Company intelligence / Profile preview

ProMedix Inc.

Portland, Oregon, United Statespromedex.com ↗

Ownership: Private
Development stage: Commercial

Overview

ProMedix has developed a noninvasive device to digitally monitor capillary refill time, aiming to improve early identification and treatment of sepsis. The company has received competitive grants from the U.S. National Science Foundation to further develop its technology. Clinical results are focused on improving accuracy in bedside sepsis detection but no published pivotal trial data yet.

Therapeutic areas: CardiovascularInfectious Diseases
Modalities: Medical devices for digital monitoring of peripheral blood flow and circulatory dysfunction
Industry: Physiological Monitoring

Partnerships

National Science Foundation SBIR/STTR grant partnershipMedTech accelerators including mHUB Chicago, Creative Destruction Lab at University of British Columbia, Health Engine Biomedical Accelerator at UC Berkeley

Beyond the preview

Go deeper on ProMedix Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProMedix Inc..

Explore the full profile